Background: Anti-phospholipid antibody syndrome is a life-threatening acquired disorder of the immune system which can lead to dysfunction of the multiple systems in the human body. Lupus anticoagulant (LA) detection by the normalized dilute Russell viper venom time (DRVVT) ratio provides a robust assay methodology with accurate results. The objective of this study was to evaluate the potential ability of diluted Russell viper-venom time (DRVVT) to identify Lupus anticoagulant (LAC) by screening and confirmation testing methods.
Methods: Samples of the suspected auto-immune disorder patients with lengthened screening dRVVT (using LA Check) more than 2 standard deviations (SD) above the average level of normal donors undergo additional testing: a 1:1 blend with normal plasma which taken from various normal individuals and amalgamated together (using LA Check) and high phospholipid confirmatory testing (using LA Sure).
Results: A total of 311 cases included in this study. Out of 311, 230 patients were females and 81 were males. Out of 230 females LAC positivity by DRVVT method was seen in 78 patients and 152 were Negative. Out of 81 males LAC positivity by DRVVT method was seen in 38 patients and 43 were Negative.
Conclusions: Precise evaluation of lupus anticoagulant plays a major role in estimating the risk factors for thrombosis. A practically elevated lupus anticoagulant result may change the duration of anticoagulation medications usage for patients. The dRVVT is recognized and certified by all three expert panels as one of the preliminary assays to be included when screening for a LAC.
How to cite this article:
Dr. Pramod Kumar Pamu. Lupus anti-coagulant (LA) screening & confirmation testing by dilute Russell viper venom time (DRVVT) method. International Journal of Clinical and Diagnostic Pathology. 2020; 3(4): 12-15. DOI: 10.33545/pathol.2020.v3.i4a.305